Update COVID-19:
The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites, we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are proactively being reassessed at regular intervals and adapted as deemed appropriate.
The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.
In December 2016, Mercachem and Almirall announced that Almirall had obtained exclusive rights to Mercachem’s cytokine blockers, and a research collaboration was initiated to optimize these molecules towards candidates for clinical development.
Today, Mercachem is proud to announce the achievement of the first milestone of this research collaboration.
“We are delighted to announce that we have achieved the first milestone within 15 months of collaboration,” said Eelco Ebbers, co-founder and Managing Director of Mercachem. “This shows the innovative research capabilities of Mercachem to progress challenging targets and chemistries, and also demonstrates the true strength of working in partnerships.”
Contact us
-
2020
-
2019
- Mercachem involved in publication on highly selective p38 MAP Kinase Inhibitors
- Dr. Russell Thomas joins MercachemSyncom as Head of BD
- Sascha Hartmann joins MercachemSyncom as Director of Business Development
- New patent on synthesis of triazoloquinazolinone compounds
- Mercachem scientists explore SAR around epigenetic enzymes EHMT1 and EHMT2
- Gotham Therapeutics and Mercachem announce progress in compound library development
- City Councilor visits Mercachem
- The European Lead Factory continues as ESCulab
- Mercachem achieves second Milestone in collaboration with Almirall
- Mercachem celebrates opening of new lab facility in Nijmegen
- Mercachem Scientists publish PROTAC Review
- Workshop "Getting Ready for Phase 1"
-
2018
- Dr. Luc van Hijfte elected member of Académie Nationale de Pharmacie
- MercachemSyncom Announces the Acquisition of Chiralix
- New SUKL Certitifate Granted!
- Mercachem Finalizes the Synthesis of 40,000 ELF Compounds
- Mercachem Tackles African Sleeping Sickness
- Mercachem Achieves the First Milestone in Collaboration with Almirall
- Setting the Future in Stone
-
2017
- Microwave-Assisted Synthesis of Drug-Like Libraries
- Finalist of the Gouden Spatel Prize 2016: Yoeri Janssen
- Mercachem–Syncom Group Announces the Appointment of Dr. Luc Van Hijfte as Senior Vice President of Medicinal Chemistry
- Mercachem celebrated its 20 years anniversary
- Mercachem and Syncom Join Forces to Form Europe’s Premier Drug Discovery CRO
- New Autotaxin Inhibitors Published by Mercachem and Galapagos
- Mercachem Patents Synthesis of IP-free Scaffolds Derived from Natural Products
- InHolland Students Show: The Future of Drug Discovery Looks Bright!
- Publication: Improved 2-oxa-6-azaspiro[3.3]heptane Synthesis
- Novel κ Agonists Reported in Journal of Medicinal Chemistry
- 30,000 Compounds for the ELF Project!
- Mercachem and Syngenta: A 15 Year Discovery Collaboration in Patents!
- Marcel Scheepstra Wins KNCV Dutch Medicinal Chemistry Prize 2015–2016
- AiCuris selects Mercachem as Preferred Medicinal Chemistry Partner
- New CIR Accreditation Granted!
- Mercachem and UbiQ Join Forces to Tackle SUMOylation
- Patent: Lisdexamfetamine Production Improved by Enzymatic Catalysis